Kazakhstan invests $862 million in domestic drug production

Kazakhstan invests $862 million in domestic drug production
Envato

Kazakhstan plans to manufacture 494 types of medicines through eight major investment projects worth a combined $862 million, Health Minister Akmaral Alnazarova announced on 3 November, local media reported.

Investment to boost domestic medicine production

The projects will be rolled out in stages, with production of the first 300 types of medicines scheduled between 2027 and 2030. More than 1,200 jobs are expected to be created.

Digital system to safeguard vaccine supplies

Kazakhstan is also introducing a unified digital system to monitor vaccine storage and transport.

According to Alnazarova, the system will detect temperature fluctuations in real time, helping to safeguard vaccine quality and strengthen oversight of immunisation programmes.

The platform will connect more than 3,500 facilities and 800 vehicles, allowing authorities to track temperatures across the supply chain, from central distribution warehouses to healthcare facilities.

Kazakhstan currently spends around 38 billion tenge ($84 million) annually on vaccines and other immunobiological products. The new system is expected to reduce waste and improve stock management.

More medicines to be provided free of charge

The government also plans to expand the range of medicines available free of charge to outpatients.

The revised list is expected to include 22 medicines used to treat 14 diseases.

Meanwhile, Kazakhstan has moved forward procurement of medicines for 2027 by three months. By early October, contracts had been signed for more than 84 per cent of the medicines on the planned procurement list. That figure is expected to reach 95 per cent by the end of the year.

New pharmaceutical plant planned in Almaty

A pharmaceutical plant backed by more than 39 billion tenge ($86 million) in investment is also planned for Almaty.

The project aims to boost domestic medicine production, support local manufacturing of international medicines and lay the groundwork for producing pharmaceutical ingredients in Kazakhstan.

The plant will be developed in phases. From 2030 to 2033, it will focus on producing finished dosage forms, transferring technology and developing the capacity for full-cycle manufacturing.

The following phase, from 2034 to 2036, will focus on manufacturing active pharmaceutical ingredients, helping to gradually reduce reliance on imported raw materials.

Read more about Kazakhstan: 

Tags